← All trials
NCT04766476
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2021
- Primary completion
- Dec 29, 2021
- Completion date
- Dec 30, 2021
- First posted
- Feb 23, 2021
- Last posted
- May 24, 2021
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.